HLS Therapeutics, Inc. (HLS.TO)
4.09
-0.11
(-2.62%)
CAD |
TSX |
Oct 09, 16:00
HLS Therapeutics Enterprise Value : 167.86M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 167.86M |
| October 08, 2026 | 171.30M |
| October 07, 2026 | 172.87M |
| October 06, 2026 | 171.30M |
| October 05, 2026 | 171.62M |
| October 02, 2026 | 160.98M |
| October 01, 2026 | 161.61M |
| September 30, 2026 | 171.30M |
| September 29, 2026 | 164.74M |
| September 28, 2026 | 165.05M |
| September 25, 2026 | 165.67M |
| September 24, 2026 | 163.17M |
| September 23, 2026 | 163.49M |
| September 22, 2026 | 163.80M |
| September 21, 2026 | 164.11M |
| September 18, 2026 | 162.24M |
| September 17, 2026 | 164.74M |
| September 16, 2026 | 165.99M |
| September 15, 2026 | 167.86M |
| September 14, 2026 | 169.74M |
| September 11, 2026 | 161.92M |
| September 10, 2026 | 156.61M |
| September 09, 2026 | 157.23M |
| September 08, 2026 | 158.17M |
| September 04, 2026 | 155.67M |
| Date | Value |
|---|---|
| September 03, 2026 | 152.54M |
| September 02, 2026 | 152.85M |
| September 01, 2026 | 157.23M |
| August 31, 2026 | 157.23M |
| August 28, 2026 | 158.48M |
| August 27, 2026 | 155.67M |
| August 26, 2026 | 154.11M |
| August 25, 2026 | 160.05M |
| August 24, 2026 | 155.36M |
| August 21, 2026 | 157.23M |
| August 20, 2026 | 163.17M |
| August 19, 2026 | 160.98M |
| August 18, 2026 | 161.92M |
| August 17, 2026 | 161.92M |
| August 14, 2026 | 161.92M |
| August 13, 2026 | 160.98M |
| August 12, 2026 | 164.42M |
| August 11, 2026 | 159.73M |
| August 10, 2026 | 162.55M |
| August 07, 2026 | 165.99M |
| August 06, 2026 | 165.05M |
| August 05, 2026 | 168.80M |
| August 04, 2026 | 168.80M |
| July 31, 2026 | 171.30M |
| July 30, 2026 | 171.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bausch Health Cos., Inc. | 31.48B |
| Cipher Pharmaceuticals, Inc. | 334.51M |
| BioSyent, Inc. | 188.68M |
| Revive Therapeutics Ltd. | 10.94M |
| Knight Therapeutics, Inc. | 988.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.412M |
| Revenue (Quarterly) | 20.31M |
| Total Expenses (Quarterly) | 21.73M |
| EPS Diluted (Quarterly) | -0.0451 |
| Gross Profit Margin (Quarterly) | 42.90% |
| Profit Margin (Quarterly) | -6.95% |
| Earnings Yield | -9.22% |
| Normalized Earnings Yield | -8.362 |